23Jan 2024
Liquid Biopsy May Help Identify Which Patients With Non-Small Cell Lung Cancer Will Benefit Most From Radiation

Liquid Biopsy May Help Identify Which Patients With Non-Small Cell Lung Cancer Will Benefit Most From Radiation

A breakthrough liquid biopsy test may revolutionize treatment decisions for non-small cell lung cancer (NSCLC) patients with widespread metastatic disease. The test analyzes circulating tumor DNA in blood to determine the extent of cancer spread. Researchers found that patients with low or undetectable levels of ctDNA benefit most from high-dose radiation, experiencing more extended survival periods. This non-invasive approach provides a more precise measure of disease burden, improving personalized treatment decisions for NSCLC patients.

  • #family health

Like

Save

Share